U.S. Markets closed

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.29+0.11 (+2.12%)
At close: 1:00PM EST

Affimed N.V.

Technologiepark
Im Neuenheimer Feld 582
Heidelberg 69120
Germany
49 6221 6743 60
http://www.affimed.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees137

Key Executives

NameTitlePayExercisedYear Born
Dr. Adi HoessCEO, MD & Member of Management BoardN/AN/A1962
Dr. Wolfgang FischerMD, COO & Member of Management BoardN/AN/A1964
Prof. Melvyn LittleFounder & ConsultantN/AN/AN/A
Mr. Angus W. SmithChief Financial OfficerN/AN/A1983
Dr. Arndt SchotteliusChief Scientific OfficerN/AN/A1966
Mr. Michael WolfHead of Fin. & Admin.N/AN/A1967
Mr. Alexander FudukidisHead of Investor RelationsN/AN/AN/A
Dr. Uwe ReuschHead of Cell CultureN/AN/AN/A
Dr. Stefan KnackmussHead of Antibody ScreeningN/AN/AN/A
Dr. Sergey KipriyanovHead of R&DN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Corporate Governance

Affimed N.V.’s ISS Governance QualityScore as of November 1, 2019 is 9. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.